106 related articles for article (PubMed ID: 23174883)
41. miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression.
Wang M; Tan LP; Dijkstra MK; van Lom K; Robertus JL; Harms G; Blokzijl T; Kooistra K; van T'veer MB; Rosati S; Visser L; Jongen-Lavrencic M; Kluin PM; van den Berg A
J Pathol; 2008 May; 215(1):13-20. PubMed ID: 18348159
[TBL] [Abstract][Full Text] [Related]
42. Promiscuity of translocation partners in multiple myeloma.
Martin LD; Belch AR; Pilarski LM
J Cell Biochem; 2010 Apr; 109(6):1085-94. PubMed ID: 20127714
[TBL] [Abstract][Full Text] [Related]
43. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.
Bergsagel PL; Kuehl WM; Zhan F; Sawyer J; Barlogie B; Shaughnessy J
Blood; 2005 Jul; 106(1):296-303. PubMed ID: 15755896
[TBL] [Abstract][Full Text] [Related]
44. Advances in biology of multiple myeloma: clinical applications.
Hideshima T; Bergsagel PL; Kuehl WM; Anderson KC
Blood; 2004 Aug; 104(3):607-18. PubMed ID: 15090448
[TBL] [Abstract][Full Text] [Related]
45. Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma.
Van Wier S; Braggio E; Baker A; Ahmann G; Levy J; Carpten JD; Fonseca R
Haematologica; 2013 Oct; 98(10):1586-92. PubMed ID: 23716545
[TBL] [Abstract][Full Text] [Related]
46. Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma.
Yang L; Wang H; Kornblau SM; Graber DA; Zhang N; Matthews JA; Wang M; Weber DM; Thomas SK; Shah JJ; Zhang L; Lu G; Zhao M; Muddasani R; Yoo SY; Baggerly KA; Orlowski RZ
Oncogene; 2011 Mar; 30(11):1329-40. PubMed ID: 21057542
[TBL] [Abstract][Full Text] [Related]
47. Downregulated miR-33b is a novel predictor associated with disease progression and poor prognosis in multiple myeloma.
Li F; Hao M; Feng X; Zang M; Qin Y; Yi S; Li Z; Xu Y; Zhou L; Sui W; Deng S; Zou D; Zhan F; Qiu L
Leuk Res; 2015 Jul; 39(7):793-9. PubMed ID: 25975752
[TBL] [Abstract][Full Text] [Related]
48. Dual Primary IGH Translocations in Multiple Myeloma: A Novel Finding.
Ravindran A; Greipp PT; Wongchaowart N; Smadbeck JB; Peterson JF; Ketterling RP; Kumar SK; Baughn LB
Clin Lymphoma Myeloma Leuk; 2021 Sep; 21(9):e710-e713. PubMed ID: 34172422
[No Abstract] [Full Text] [Related]
49. A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma.
Bolli N; Li Y; Sathiaseelan V; Raine K; Jones D; Ganly P; Cocito F; Bignell G; Chapman MA; Sperling AS; Anderson KC; Avet-Loiseau H; Minvielle S; Campbell PJ; Munshi NC
Blood Cancer J; 2016 Sep; 6(9):e467. PubMed ID: 27588520
[TBL] [Abstract][Full Text] [Related]
50. A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5.
White BS; Lanc I; O'Neal J; Gupta H; Fulton RS; Schmidt H; Fronick C; Belter EA; Fiala M; King J; Ahmann GJ; DeRome M; Mardis ER; Vij R; DiPersio JF; Levy J; Auclair D; Tomasson MH
Blood Cancer J; 2018 Mar; 8(3):35. PubMed ID: 29563506
[TBL] [Abstract][Full Text] [Related]
51. VOLIN and KJON-Two novel hyperdiploid myeloma cell lines.
Våtsveen TK; Børset M; Dikic A; Tian E; Micci F; Lid AH; Meza-Zepeda LA; Coward E; Waage A; Sundan A; Kuehl WM; Holien T
Genes Chromosomes Cancer; 2016 Nov; 55(11):890-901. PubMed ID: 27311012
[TBL] [Abstract][Full Text] [Related]
52. A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative PCR.
Kaiser MF; Walker BA; Hockley SL; Begum DB; Wardell CP; Gonzalez D; Ross FM; Davies FE; Morgan GJ
Leukemia; 2013 Aug; 27(8):1754-7. PubMed ID: 23318961
[No Abstract] [Full Text] [Related]
53. Blind men and an elephant.
Kumar S
Blood; 2015 Jan; 125(5):745-7. PubMed ID: 25634613
[TBL] [Abstract][Full Text] [Related]
54. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.
Fonseca R; Bergsagel PL; Drach J; Shaughnessy J; Gutierrez N; Stewart AK; Morgan G; Van Ness B; Chesi M; Minvielle S; Neri A; Barlogie B; Kuehl WM; Liebisch P; Davies F; Chen-Kiang S; Durie BG; Carrasco R; Sezer O; Reiman T; Pilarski L; Avet-Loiseau H;
Leukemia; 2009 Dec; 23(12):2210-21. PubMed ID: 19798094
[TBL] [Abstract][Full Text] [Related]
55. Amplification of 1q21 and other abnormalities in multiple myeloma patients from a tertiary hospital in singapore.
Lim AS; Krishnan S; Lim TH; See K; Ng YJ; Tan YM; Choo N; Lau LC; Tien SL; Ma J; Tan D
Indian J Hematol Blood Transfus; 2014 Dec; 30(4):253-8. PubMed ID: 25435723
[TBL] [Abstract][Full Text] [Related]
56. Additional comments regarding IGH studies in multiple myeloma.
Smith SC; Althof PA; Dave BJ; Sanmann JN
Genes Chromosomes Cancer; 2021 Jan; 60(1):55. PubMed ID: 32949443
[No Abstract] [Full Text] [Related]
57. The genetic architecture of multiple myeloma.
Prideaux SM; Conway O'Brien E; Chevassut TJ
Adv Hematol; 2014; 2014():864058. PubMed ID: 24803933
[TBL] [Abstract][Full Text] [Related]
58. The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma.
Cirrincione AM; Poos AM; Ziccheddu B; Kaddoura M; Baertsch MA; Maclachlan KH; Chojnacka M; Diamond BT; John L; Reichert P; Huhn S; Blaney P; Gagler DC; Rippe K; Zhang Y; Dogan A; Lesokhin AM; Davies FE; Goldschmidt H; Fenk R; Weisel KC; Mai EK; Korde N; Morgan GJ; Usmani SZ; Landgren O; Raab MS; Weinhold N; Maura F
Blood; 2024 May; ():. PubMed ID: 38728430
[TBL] [Abstract][Full Text] [Related]
59. Multiethnic myeloma.
Weiss BM
Blood; 2013 Apr; 121(16):3062-4. PubMed ID: 23599258
[No Abstract] [Full Text] [Related]
60. Cell lines of hyperdiploid myeloma, are we there yet?
Chng WJ; Fonseca R
Br J Haematol; 2008 Mar; 140(5):579-80; author reply 580-1. PubMed ID: 18028478
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
